BeOne Medicines’ Baker-related beneficial ownership position is reported at 7.8% after the Acquisition of 30,768 ADS through exercised Options at $36.83 per ADS. The adviser controls the timing and disposition of the exercised ADS, while the group says it has no plans for an extraordinary corporate transaction involving BeOne Medicines.
Key Highlights
- The two funds report combined ownership of 114,387,735 Ordinary Shares, representing 7.7% of the class.
- The exercised ADS cost $1,133,185.44 in aggregate, with $566,592.72 paid for each holder’s options.
- Baker-related holders say they have no plans for an extraordinary corporate transaction involving BeOne Medicines.
BeOne Medicines Ltd. (NASDAQ: ONC) has a Baker-related beneficial ownership position reported at 7.8% after the acquisition of 30,768 ADS through exercised options. The options were exercised at $36.83 per ADS by Ranjeev Krishana and Michael Goller, who previously served on BeOne Medicines’ board as representatives of the funds. The Schedule 13D/A identifies the position as an activist stake, while the group says it has no plans for an extraordinary corporate transaction involving BeOne Medicines.
Baker Funds Report 7.7% Position
The reported fund holdings comprise 9,498,367 Ordinary Shares for 667, L.P. and 104,889,368 Ordinary Shares for Baker Brothers Life Sciences, L.P. The two funds’ combined position is listed at 114,387,735 Ordinary Shares, or 7.7% of the class. Baker Bros. Advisors (GP) LLC are each associated with 115,457,154 Ordinary Shares and a reported 7.8% interest. Julian C. Baker and Felix J. Baker are each associated with 115,912,814 Ordinary Shares and a reported 7.8% interest. FBB3 LLC is listed with 144,517 Ordinary Shares and a 0.01% interest. Felix J. Baker currently serves on BeOne Medicines’ board as a representative of the funds. The reported holdings include Ordinary Shares held through ADS, shares held directly and interests associated with the former directors.
Options Exercise Creates ADS Interest
The exercised options were held directly by Krishana and Goller. Each received 15,384 ADS from the exercise, producing the combined acquisition reported in the amendment. The amount spent was $566,592.72 for the options held by each of Krishana and Goller, or $1,133,185.44 in aggregate. Advisors LP funded the exercises through loans from 667 and Baker Brothers Life Sciences. Advisors LP on September 14, 2026. Under those agreements, the adviser controls when the options are exercised and has dispositive power over the ADS received through exercise. The former directors have no voting or dispositive power over the exercised options or ADS and no direct pecuniary interest in them.
No Extraordinary Deal Plans
The proceeds agreements require Krishana and Goller to hold the ADS in brokerage accounts until the adviser directs a sale. The agreements also require them to sell all or part of the ADS as directed by the adviser and remit the resulting cash. Krishana and Goller each continue to hold Share Options received for previous board service. Those options remain exercisable until the earlier of their original expiration dates or three years from the end of the respective board service. The group states that it has no plans or proposals for an extraordinary corporate transaction involving BeOne Medicines, including the matters identified in the Schedule 13D framework.



Please wait processing your request...